139481-33-7

Basic information

• Product Name: Azilsartan iMpurity I
• Synonyms: Azilsartan iMpurity I;Methyl 1-((2'-cyanobiphenyl-4-yl) Methyl)-2H-benziMidazol-2-one-7-carboxylate);Methyl 3-((2'-cyanobiphenyl-4-yl)Methyl)-2-oxo-2,3-dihydro-1H-benzo[d]iMidazole-4-carboxylate;methyl 3-((2'-cyano-[1,1'-biphenyl]-4-yl)methyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-4-carboxylate;zilsartan iMpurity I
• CAS NO: 139481-33-7
• Molecular Formula: C₂₃H₁₇N₃O₃
• Molecular Weight: 383.39938
• Mol File: 139481-33-7.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Density: 1.37±0.1 g/cm3(Predicted)
• PKA: 11.32±0.30(Predicted)
• CAS DataBase Reference: Azilsartan iMpurity I(CAS DataBase Reference)
• NIST Chemistry Reference: Azilsartan iMpurity I(139481-33-7)
• EPA Substance Registry System: Azilsartan iMpurity I(139481-33-7)

Safety Data

• Hazardous Substances Data: 139481-33-7(Hazardous Substances Data)

Usage

Uses

Methyl 3-[(2''-Cyano[1,1''-biphenyl]-4-yl)methyl]-2,3-dihydro-2-oxo-1H-benzimidazole-4-carboxylate, is an impurity of Azilsartan (A926900), an analgesic and antiinflammatory drugs containing angiotensin II antagonists.

Upstream product

• 139481-44-0 methyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-ethoxy-benzimidazole-7-carboxylate 
• 139481-41-7 ethyl 1-[(2'-cyano-[1,1']-biphenyl-4-yl)methyl]-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate 
• 139481-38-2 methyl 2-amino>-3-nitrobenzoate 
• 139481-28-0 methyl 2-<<2'-cyanobiphenyl-4-yl)methyl>amino>-3-nitrobenzoate 
• 136304-78-4 methyl 3-amino-2-[[(2'-cyanobiphenyl-4-yl)methyl]amino]benzoate 
• 856414-36-3 2-Azidocarbonyl-3-nitro-benzoic acid methyl ester 
• 57113-90-3 methyl 2-(N-tert-butoxycarbonylamino)-3-nitrobenzoate 
• 603-11-2 3-nitrophthalic acid 
• 73833-13-3 acid chloride of 1-methylhydrogen-3-nitrophthalate 
• 21606-04-2 methyl 2-carboxy-3-nitrobenzoate 
• 139481-35-9 methyl 2-<<(2'-cyanobiphenyl-4-yl)methyl>amino>-3-<(methoxycarbonyl)amino>benzoate 

Downstream Products

• 1499167-72-4 methyl 3-((2'-(N'-hydroxycarbamimidoyl)biphenyl-4-yl)methyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-4-carboxylate 
• 139481-97-3 2-Morpholin-4-yl-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid methyl ester 
• 139481-98-4 2-Piperidin-1-yl-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid methyl ester 
• 139481-51-9 methyl 1-<(2'-cyanobiphenyl-4-yl)methyl>-2-morpholino-1H-benzimidazole-7-carboxylate 
• 139481-52-0 methyl 1-<(2'-cyanobiphenyl-4-yl)methyl>-2-piperidino-1H-benzimidazole-7-carboxylate 
• 139481-34-8 methyl 2-chloro-1-<(2'-cyanobiphenyl-4-yl)methyl>-1H-benzimidazole-7-carboxylate 

Relevant articles and documents

A [...] process impurity D synthetic method

The invention discloses a process of impurity D [...] synthetic method. To methyl [...] A1 as raw materials, under acidic conditions to produce intermediate de-ethyl A2, intermediate A2 through hydrolysis to produce intermediate A3, A3 and then with hydro

A METHOD OF MANUFACTURING 2-ETHOXY-1-((2'-((HYDROXYAMINO) IMINOMETHYL)BIPHENYL-4- YL)METHYL)-1H-BENZO [D] IMIDAZOLE-7-CARBOXYLIC ACID AND ITS ESTERS

A method of manufacturing 2-ethoxy-1 -((2'-((hydroxyamino)iminomethyl)biphenyl-4- yl)methyl)-1H-benzo[d]imidazole-7-carboxylic acid and its esters of formula I, wherein R is either H or an (un)branched C1-C4 alkyl, ArCH2, Ar2CH, or Ar3C, wherein Ar is a (un)substituted phenyl, the key intermediates for the synthesis of azilsartan, the reaction of the corresponding nitrile of formula IV being carried out with aqueous hydroxylamine in a polar aprotic solvent, or in a mixture of such solvents.

Nonpeptide Angiotensin II Receptor Antagonists. Synthesis and Biological Activity of Benzimidazolecarboxylic Acids

A series of 2-substituted-1--1H-benzimidazole-7-carboxylic acids was prepared from the key intermediate 3-amino-2-amino>benzoate (6a-c) in order to clarify the structure-activity relationships of various analogues of 2-butyl-1-methyl>-1H-benzimidazole-7-carboxylic acid (CV-11194), a potent and long acting angiotensin II (AII) receptor antagonist.The AII antagonistic activity of the benzimidazoles was investigated by in vitro assays, which included an AII receptor binding assay and AII-induced vasocontraction assay, as well as by in vivo assays such as an AII-induced pressor response in rats.Most of the benzimidazoles showed high affinity for the AII receptor (IC50 value, 10-6-1--7 M) and inhibited the AII-induced pressor response at 1 or 3 mg/kg po, and the effects were more potent than those of CV-11194 and DuP 753.The structure-activity relationship studies on the binding affinity and the inhibition of AII-induced pressor response suggested that straight chains of a certain length (e.g., ethoxy groups, ethyl groups) were the best as substituents at the 2-position and that their steric factors, lipohilicity, and electronic effects affected the potency of the AII antagonistic action.Both a carboxyl group at the 7-position and a tetrazole ring at the 2'-position were particularly important for potent and orally active AII antagonistic activity and a long-acting hypotensive effect.The representative compound, 2-ethoxy-1-methyl>-1H-benzimidazole-7-carboxylic acid (26b, CV-11974), inhibited the specific binding of AII to bovine adrenal cortical membrane with an IC50 value of 1.1*10-7 M.The AII-induced contraction of rabbit aortic strips was antagonized by CV-11974 (IC50 value, 3.0*1--10 M).Oral administration of CV-11974 to conscious normatensive rats at 1 mg/kg resulted in long-lasting inhibition of the AII-induced pressor response.CV-11974 at 0.1-1 mg/kg iv reduced blood pressure dose-dependently in spontaneously hypertensive rats.